Journal of Histochemistry and Cytochemistry, Vol. 49, 209-218, February 2001, Copyright © 2001, The Histochemical Society, Inc.


ARTICLE

Tissue Activity and Cellular Localization of Human Semicarbazide-sensitive Amine Oxidase

Noemí Andrésa, José Miguel Lizcanob, Manuel J. Rodrígueza, Manuel Romerab, Mercedes Unzetab, and Nicole Mahya
a Unitat de Bioquímica, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain
b Departament de Bioquímica, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain

Correspondence to: Nicole Mahy, Unitat de Bioquímica, Facultat de Medicina, UB, C/Casanova, 143, Barcelona E-08036, Spain. E-mail: mahy@medicina.ub.es


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Semicarbazide-sensitive amine oxidase (SSAO), widely distributed in highly vascularized mammalian tissues, metabolizes endogenous and xenobiotic aromatic and aliphatic monoamines. To assess whether its physiological role in humans is restricted to oxidation, we used an immunohistochemical approach to examine the cellular localization of SSAO in human peripheral tissues (adrenal gland, duodenum, heart, kidney, lung, liver, pancreas, spleen, thyroid gland, and blood vessels) and also analyzed its subcellular localization. The results are in agreement with the specific activities also determined in the same samples and are discussed with reference to the tissue distribution of monoamine oxidase A and B. Together with the oxidative deamination of monoamines, SSAO cellular localization indicates that, in most human peripheral tissues, it might participate in the regulation of physiological processes via H2O2 generation. (J Histochem Cytochem 49:209–217, 2001)

Key Words: semicarbazide-sensitive amine, oxidase (SSAO), human peripheral tissues, immunohistochemistry, enzymology


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

AMINE OXIDASES metabolize monoamines, diamines, and polyamines of endogenous or xenobiotic origin, rendering ammonia, aldehydes, and hydrogen peroxide as final products. According to their co-factor, amine oxidases are classified into two groups. The FAD-dependent amine oxidases (E.C.1.4.3.4.) are sensitive to acetylenic type inhibitors, which include the monoamine oxidases (MAO) and polyamine oxidases. In the second group, the Cu-dependent amine oxidases (E.C.1.4.3.6), sensitive to carbonyl reagents such as semicarbazide, comprise the diamine oxidase and semicarbazide-sensitive amine oxidase (SSAO), which deaminates both aromatic and aliphatic primary amines, such as methylamine and aminoacetone.

SSAO activity is present in blood plasma and is associated with membranes in several mammalian tissues (Lewinsohn 1984 ). Tissue-bound SSAO has been described in many mammalian tissues, especially in those that are highly vascularized (Lyles 1996 ), and blood vessels (Precious and Lyles 1988 ). SSAO activity has also been found in nonvascular tissues, such as adipocytes (Barrand et al. 1984 ; Morris et al. 1997 ), odontoblasts (Norqvist et al. 1981 ), and different parts of the bovine eye (Fernandez de Arriba et al. 1991 ) (see Lyles 1996 for review).

Despite its widespread tissue distribution, the physiological role of SSAO is far from understood. Together with its amine oxidase activity, SSAO might participate in the regulation of glucose disposal in several insulin-sensitive tissues, including cardiac and skeletal muscle and adipocytes, where it is associated with the glucose transporter GLUT4 (Enrique-Tarancon et al. 1998 ). A vascular adhesion protein, VAP-1, with identical sequence to the tissue-bound SSAO has recently been described (Smith et al. 1998 ; Bono et al. 1998 ). Because VAP-1 is involved in lymphocyte migration to lymphoid organs, a new physiological role for SSAO in cellular trafficking has been suggested (Smith et al. 1998 ; Jaakkola et al. 1999 ).

Changes in plasma SSAO activity have been related to several pathological situations. Plasma SSAO activity is reduced in patients suffering from burns (Lewinsohn 1984 ), fibrotic liver disease (Lewinsohn 1984 ), and diabetes mellitus (Boomsma et al. 1995 ). A decrease in tissue-bound SSAO activity accompanied by malignancy has also been reported in chemically induced rat breast tumors (Lizcano et al. 1991 ). Finally, the formaldehyde generated from methylamine metabolism by SSAO in vascular tissues has been proposed as a risk factor in stress-related angiopathy (Yu et al. 1997 ).

To better understand the physiological role of SSAO, the activity and cellular distribution of SSAO were determined in human tissues, including adrenal gland, duodenum, heart, kidney, lung, liver, pancreas, spleen, thyroid gland, and blood vessels, by enzymatic and immunohistochemical techniques using a specific antibody against tissue-bound SSAO (Castillo et al. 1998 ; Lizcano et al. 1998 ). Because MAO-A and -B may contribute to amine oxidation, their activities were also determined in these tissues. Because the role of SSAO has been related to a dual cellular distribution in some cells (Lizcano et al. 1991 ; Smith et al. 1998 ), its localization was also studied in the labeled cell types from each of these peripheral tissues. Finally, our results are compared with the MAO-A and -B distribution previously reported. (Saura et al. 1997 ; Rodriguez et al. 2000 ).


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Human Tissues
Human tissues were generously provided by Dr. J. A. Bombí (Facultat de Medicina, Universitat de Barcelona, Spain) in accordance with local institutional ethical guidelines. Samples of adrenal gland, duodenum, heart, kidney, lung, liver, pancreas, spleen, thyroid gland, and vessels were obtained from nine routine autopsy cases (five men and four women). Tissues affected by the pathological state of the patient were discarded. The age range was 50–84 years (mean ± SEM, 72.2 ± 3.7) and the postmortem delay ranged from 4 to 22 hr (12.6 ± 1.9).

Immediately after autopsy, tissues were divided into two groups. One group was cut into 1–2-cm-thick blocks for the immunohistochemical studies and the other was stored in liquid nitrogen for enzymatic activity determination.

Enzyme Assays
Samples kept in liquid nitrogen were powdered with a mechanical hammer. They were then homogenized 1:10 (w/v) in 50 mM Na+, K+ phosphate buffer, pH 7.6, and filtered through a double gauze. Aliquots were taken and stored at -80C.

SSAO and MAO-B activities were determined radiochemically (Fowler and Tipton 1981 ) with 100 µM [7-14C]-benzylamine (55 mCi/mmol; Amersham, Madrid, Spain) as substrate. MAO-A activity was measured towards 100 µM [14C]-5-HT (55 mCi/mmol; Amersham) as specific substrate. Because SSAO and MAO-B are both active towards benzylamine, MAO-B was previously inhibited with 1 mM deprenyl for SSAO determinations and SSAO was inhibited with 1 mM semicarbazide for MAO-B assays. After preincubation with the corresponding inhibitor for 30 min, each enzymatic reaction (150–220 µg of protein) was carried out at 37C for 1 hr in a shaking water bath in a final volume of 225 µl 50 mM potassium phosphate buffer, pH 7.6, stopped by 100 µl 2 M citric acid, and the radioactivity directly counted after a 4-ml addition of scintillation liquid (Lizcano et al. 1998 ). MAO-A activity was determined in similar conditions using an incubation time of 30 min.

Time-course assays were used to ensure that initial rates of the reaction were determined, and proportionality to enzyme concentration was established in each case. Protein was measured by the Bradford method (Bradford 1976 ), using {gamma}-globulin as standard. All nonradioactive products were purchased from Sigma (St Louis, MO).

Immunoblotting Analysis
Human tissues homogenates or purified porcine kidney diamine oxidase (Sigma) were fractionated by electrophoresis on 8% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Blots were blocked for 1 hr at room temperature with 5% (w/v) non-fat dried milk in 20 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 0.05% Tween-20, then incubated with primary anti-SSAO antibody (1:500 dilution) overnight at 4C, followed by incubation for 1 hr with secondary antibody. Finally, the blots were developed with the avidin–biotin–peroxidase technique, following the manufacturer's instructions (Vector Laboratories; Bretton, UK). After color development, the membrane was washed with distilled water, air-dried, and photographed. Prestained molecular weight standards used were myosin (250 kD), bovine serum albumin (98 kD), glutamate dehydrogenase (64 kD), alcohol dehydrogenase (50 kD), carbonic anhydrase (36 kD), and myoglobin (30 kD) from Novex (San Diego, CA).

Immunohistochemical Assays
After autopsy, 1–2-cm tissue blocks were immediately fixed by immersion in paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, at 4C. Different fixation times (2, 4, 7, or 24 hr) and fixative concentrations [0, 0.1, 1, 2, 4 % (w/v)] were tested. After fixation, tissues were immersed for 72 hr in 15% (w/v) sucrose in 0.1 M phosphate buffer, pH 7.4, for cryoprotection, frozen with dry ice, and stored at -30C. Sections of fresh frozen tissue were also postfixed with acetone or paraformaldehyde 4% (w/v) for 2 or 5 min.

Cryostat sections (12 µm) were cut from the fixed tissue blocks and mounted on gelatinized slides. The immunohistochemical avidin–biotin method was used. Endogenous peroxidase activity was inhibited by a 30-min preincubation in 30% (v/v) H2O2 in 10 mM Tris-buffered saline (TBS), pH 7.6, followed by a 15-min wash in TBS. Then sections were incubated in 20% (v/v) normal goat serum (NGS) in TBS for 20 min. A rabbit polyclonal anti-bovine SSAO antibody (Castillo et al. 1998 ; Lizcano et al. 1998 ) was used diluted in TBS–1% NGS as primary antibody for detection of SSAO protein. Incubation was performed overnight at 4C and antibody dilutions of 1:200, 1:300, 1:400, and 1:500 were tested. The antibody 9H7 (an anti-{gamma}-gliadin, which has been typed as subclass IgG1) was diluted 1:400 and used to define the nonspecific staining. After washing, sections were incubated for 30 min at room temperature in biotinylated goat anti-rabbit IgG (1:300 in TBS–1% NGS), rinsed, and washed in TBS, and then incubated for 2 hr at room temperature in ExtraAvidin–horseradish peroxidase (1:250 in TBS–1% NGS). After washing, sections were developed for 15 min in a 50 mM Tris-HCl solution, pH 7.6, containing 0.03% (w/v) diaminobenzidine and 0.006% (v/v) H2O2. Some sections were counterstained with Mayer's hematoxylin for morphology. Secondary antibodies and reagents were purchased from Sigma.


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Specific Activities
Specific activities of MAO-A, MAO-B, and SSAO were detected in most of the tissues assayed, with marked differences (see Table 1). The highest specific activity of MAO-A was observed in liver, duodenum, and kidney (1003–1158 pmol·min-1·mg prot-1). Heart, lung, thyroid and adrenal glands presented about half the value found in the former tissues, and aorta, spleen, muscle, and vena cava showed the lowest activity. Low activity was detected in pancreas. For MAO-B, the highest activity was found in heart, liver, duodenum, and kidney (209–322 pmol·min-1·mg prot-1). Half this amount was found in adrenal gland, and negligible activity was observed in pancreas and spleen.


 
View this table:
[in this window]
[in a new window]
 
Table 1. MAO-A, MAO-B, and SSAO specific activities in human peripheral tissues (pmol·min-1·mg prot-1)a

SSAO specific activity was found in all the tissues assayed. Aorta showed the highest activity (338 pmol· min-1·mg prot-1); lung, duodenum, and venous cava showed lower activity (86–133 pmol·min-1·mg prot-1) and the remaining tissues much lower (<54 pmol·min-1·mg prot-1). Comparison of MAO-B and SSAO contribution to benzylamine oxidative deamination indicates that SSAO is the main oxidase in aorta, pancreas, lung, and vena cava, whereas MAO-B is the main oxidase in heart, liver, duodenum, kidney, and adrenal gland.

Distribution and Cellular Localization of SSAO Immunoreactivity
To test the specificity of the polyclonal antibody anti-SSAO used in this study, immunoblotting analysis were performed using different human tissue homogenates. Fig 1 (Lanes 1 and 2) shows that human heart and adrenal gland homogenates rendered a single immunoreactive band of 100 kD, similar to the apparent molecular weight of SSAO protein reported in bovine (Lizcano et al. 1998 ) and rat (Enrique-Tarancon et al. 1998 ). Furthermore, the possibility that the antibody used might also recognize a related Cu-dependent amine oxidase was discarded. No immunoreactivity was observed when porcine kidney diamine oxidase of 93 kD molecular weight (Schwelberger and Bodner 1997 ) was assayed (Fig 1, Lanes 3 and 4), and no signal was detected at 84 kD, the molecular weight of the human form (Morel et al. 1992 ) not commercially available.



View larger version (33K):
[in this window]
[in a new window]
 
Figure 1. Specificity of the anti-SSAO antibody. Immunoblotting analysis was performed using a rabbit antibody directed against purified bovine lung SSAO. Each sample was electroblotted after 8% SDS-PAGE and stained as described in the text. Lane 1, 10 µg of human heart homogenate; Lane 2, 10 µg of human adrenal gland homogenate; Lane 3, 1 µg of purified porcine kidney diamine oxidase; Lane 4, 10 µg of purified porcine kidney diamine oxidase. Mw, prestained molecular weight standards.

Widespread SSAO distribution was observed in all tissues except the thyroid gland and endocrine pancreas, which were devoid of specific SSAO immunoreactivity (IR) (Fig 2 and Fig 3; Table 2 and Table 3). In most tissues, SSAO IR appeared to be bound to the cytoplasmic membrane of the labeled cells. Only a weak and diffuse stain was detected in the presence of the 9H7 antibody. The optimal condition for fixation was found to be 7 hr of immersion in 2% paraformaldehyde. Longer fixation times and higher paraformaldehyde concentrations reduced the intensity of staining. Postfixation with acetone was discarded because of poor tissue preservation. A primary antibody dilution of 1:400 was considered an optimal compromise because higher dilution reduced the signal in several tissues.



View larger version (166K):
[in this window]
[in a new window]
 
Figure 2. SSAO and 9H7 staining in adjacent sections of adrenal gland, duodenum, heart, kidney, and liver. (a) All cells in adrenal cortex showed strong SSAO IR in the cytoplasm and the membrane. 9H7 IR was very weak in the adrenal cortex (b). (c) Some scattered cells (arrowhead) in the medulla of adrenal gland were SSAO-immunopositive. (d) 9H7 IR in adrenal medulla. (e) Duodenum showed SSAO IR in enterocytes (arrowhead) and muscularis mucosae cells (arrow). (f) Nonimmune control of duodenum. (g) Muscle layers of duodenum also showed SSAO IR. (h) All cardiomyocytes showed SSAO IR in the cytoplasm. (i) A cardiomyocyte showing intracellular SSAO IR. (j) 9H7 IR in a section of heart. (k) SSAO IR was present in all tubuli of the kidney (arrowhead) but not in the glomeruli (arrow). (l) A distal convoluted tubulus showing strong intracellular SSAO IR. (m) 9H7 IR in the cortex of the kidney. (n) SSAO immunostaining in the liver. (o) A hepatocyte showing stronger SSAO IR in the membrane than inside the cell. (p) Nonimmune control of liver. Bars: a–d,i,o = 30 µm; e–g = 125 µm; h,j,k,m,n,p = 250 µm; l = 60 µm.



View larger version (143K):
[in this window]
[in a new window]
 
Figure 3. SSAO and 9H7 staining in adjacent sections of lung, spleen, pancreas, and vessels. (a) SSAO IR in lung. (b) 9H7 immunostaining in an adjacent section. (c) SSAO IR in the white pulp around a vein of the spleen. (d) 9H7 IR in the same vein. (e) SSAO staining in the pancreas, with the islet of Langerhans devoid of staining (arrowhead). (f) Acinar cells of the exocrine pancreas showing strong intracellular IR. (g) Nonimmune control in exocrine pancreas. (h) Epithelial cells of pancreatic ducts show SSAO IR in the plasma membrane. (i) Nonimmune control in the same duct. (j) An artery of the kidney, showing strong SSAO IR in the fibroblasts of the elastica. (k) 9HT IR in the same artery. (m) Two lymphatic vessels of the kidney showing SSAO IR in the membrane. Bars: a,b,e = 125 µm; c,d,g–l = 30 µm; f = 60 µm.


 
View this table:
[in this window]
[in a new window]
 
Table 2. SSAO cellular localization in human adrenal gland, duodenum, heart, kidney, and livera


 
View this table:
[in this window]
[in a new window]
 
Table 3. SSAO cellular localization in human lung, pancreas, spleen, thyroid, and vesselsa

In the adrenal gland, strong SSAO IR was observed in the cytoplasmic membrane, and also intracellularly in the capsule cells. Intracellular positive staining was also seen in both secretory and interstitial cells of the cortex (Fig 2a and Fig 2b). A weak SSAO stain was seen in the medulla, where most cells were negative, and the only SSAO IR was observed in the wall of the central vein and in some scattered cells (Fig 2c and Fig 2d).

In duodenum, SSAO IR was present mostly in the membrane of the enterocytes of villi and Lieberkühn crypts. However, the cytoplasm of the muscularis mucosa and both outer and inner muscular layers showed strong SSAO IR (Fig 2e–2g). No signal was found in the Brunner glands.

In heart, a strong intracellular SSAO IR was found in the cardiomyocytes but not in the surrounding connective tissue (Fig 2h–2j). In kidney, intracellular SSAO IR was observed in the epithelial cells of renal tubuli, whereas stronger staining was seen in the collecting ducts. Glomeruli were devoid of SSAO IR because neither Bowman's capsule nor podocytes showed specific staining (Fig 2k–2m). Interstitial tissue was also devoid of SSAO staining.

In liver, strong SSAO IR was observed intracellularly and in the membranes of hepatocytes (Fig 2n–2p). A similar pattern was observed in the bile duct and central vein. No portal-to-central vein IR gradient was detected.

In lung, strong staining was detected in bronchiolar cells, both ciliated and Clara cells, and in all pneumocytes of alveoli (Fig 3a and Fig 3b). In this tissue, SSAO IR was stronger in the membrane than in the cytoplasm. In spleen, SSAO staining was observed in the membrane of the capsule and trabecular cells, and in some cells in the white pulp (Fig 3c and Fig 3d). In contrast, no signal was detected in the red pulp, and spleen lymphocytes were negative for SSAO. In the thyroid gland, all the follicular and parafollicular cells were SSAO IR-negative (not shown).

In the exocrine pancreas, intracellular SSAO IR was seen in all acinar cells (Fig 3e–3g). Centroacinar cells, intercalated ducts, and epithelial cells of pancreatic ducts showed specific IR in the cell membrane (Fig 3h and Fig 3i). The walls of pancreatic ducts and the connective tissue showed no SSAO-specific staining. The endocrine pancreas was devoid of SSAO IR.

In all the organs studied, endothelial cells of arteries and veins were devoid of anti-SSAO staining. However, fibroblasts surrounding the internal elastic lamina of arteries observed at a higher magnification showed strong membrane and intracellular SSAO IR (Fig 3j and Fig 3k). A moderate level of IR was seen in the membrane of vascular muscle-layer cells. In contrast to blood vessels, endothelial cells of lymphatic vessels gave a very strong SSAO IR (Fig 3l). Because these cells are very narrow, we were unable to localize more precisely their SSAO label.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

We have studied the human tissue and cellular distribution of SSAO using a polyclonal SSAO antibody (Castillo et al. 1998 ; Lizcano et al. 1998 ). MAO-A-, MAO-B-, and SSAO-specific activities have also been determined in these tissues to help understand the physiological role of these oxidases. In studying human postmortem samples, factors such as age, postmortem delay, and cause of death are a source of variability. The present study should be regarded as a description of the SSAO activity and localization in tissues of aged humans, which may not be applicable to younger individuals. We excluded tissues that might have been affected by the pathological condition of the donor, and because the pattern of distribution for a given tissue was the same in all the cases included, we are confident that the results reflect the non-pathological condition.

Our results confirm the presence of MAO-A, MAO-B, and SSAO in most human peripheral tissues, with a higher MAO-A specific activity. In agreement with previous reports (Lewinsohn 1984 ; Lyles 1996 ), SSAO specific activity was high in aorta and lung, whereas heart, spleen, and thyroid gland presented low activity. Values obtained in aorta, skin, and liver were similar to those previously described (Lewinsohn 1984 ; Yu et al. 1994 ). Human heart SSAO activity was much lower than that described for rat (Lyles and Callingham 1975 ). These species differences, also reported for MAO-A and -B (Saura et al. 1994 , Saura et al. 1996 ) and for SSAO (Morgan 1985 ; Lizcano et al. 1991 ), should be kept in mind when experimental data are extrapolated from rodent studies to humans.

SSAO specific activities found in this study are mainly in accordance with their tissue distribution revealed by immunohistochemistry. The high specific activity and strong immunostaining found in highly vascularized tissues such as duodenum, liver, lung, and blood vessels, but not heart, could reflect the metabolic deamination of the circulating amines of endogenous or exogenous origin.

The presence of SSAO in adrenal gland, kidney, exocrine pancreas, and lymphatic vessels in cells lacking MAO-B (Saura et al. 1997 ; Rodriguez et al. 2000 ) suggests its participation in amine oxidation, as proposed for vascular smooth muscle (Lewinsohn 1984 ; Lyles 1996 ). The adrenal gland is the main producer of hormonal catecholamines. Therefore, it is interesting to note that we found no SSAO IR in chromaffin cells. However, we found SSAO IR in the central vein, ganglionar, capsular, and interstitial cells. The absence of both SSAO and MAOs in human chromaffin cells (Rodriguez et al. 2000 ) suggests that they lack uptake mechanisms for amines that will be inactivated in the target organs. It is important to note the presence of SSAO IR in the capsule and interstitial cells because they were devoid of MAO-B (Rodriguez et al. 2000 ). In the adrenal cortex, SSAO IR was present in the membrane and cytoplasm of all secretory cells, where it might reinforce the MAO-B autocrine regulation (Rodriguez et al. 2000 ). We found that SSAO is localized in all renal tubuli. Because dopamine may be degraded by MAO-B and SSAO (Lizcano et al. 1991 ), both enzymes may be involved in the degradation of dopamine synthesized in the kidney (Lee 1982 ).

In the production of pancreatic juice, there is a contribution from two cell types from the exocrine pancreas: acinar cells, producing digestive enzymes and co-factors, and centroacinar/duct cells, producing bicarbonate and water. We found SSAO in both cell populations where MAO-A is also present, whereas MAO-B appears only in the centroacinar/duct cells (Rodriguez et al. 2000 ). Sympathetic norepinephrine is unlikely to be a MAO substrate in these cells because the sympathetic innervation of the exocrine pancreas is mainly, if not entirely, vascular (Magee 1989 ). Circulating monoamines are the most likely SSAO and MAO substrates in these cells, but monoamine uptake mechanisms have not been described. Another candidate is dopamine, because it modulates the pancreatic flow rate in rat (Mori et al. 1979b ) and accumulates in rat acinar cells after nonspecific MAO inhibition (Mori et al. 1979a ). Moreover, rat acinar cells synthesize dopamine (Mori et al. 1979b ), which inhibits amylase and bicarbonate secretion in humans (Caldara et al. 1978 ).

In addition, SSAO IR was observed only in the membrane of the smooth muscle of the blood vessels, probably related to the sympathetic regulation of blood pressure (Lyles 1996 ). Strong IR for SSAO was found in vascular fibroblasts, intracellularly and in the cytoplasmic membrane, which is consistent with the known presence of SSAO in blood vessels, predominantly associated with the smooth muscle cells (Castillo et al. 1998 ), and may be related to the reported secreted soluble form of SSAO from cultured vascular smooth muscle cells (Hysmith and Boor 1987 ). However, SSAO was absent in endothelial cells of blood vessels but present in endothelial cells of lymphatic vessels. VAP-1, an adhesion protein with the same primary structure as tissue-bound SSAO, has been located in the endothelial wall of the high endothelial venules (Bono et al. 1999 ). Expressed in inflammatory conditions, it binds to lymphocytes and helps them to migrate between endothelial cells into lymphoid organs (Jaakkola et al. 1999 ). The presence of SSAO IR in lymphatic vessels and brain microvessels (Castillo et al. 1998 ), but not in endothelial cells of large blood vessels, might reflect its duality as an enzyme and an adhesion protein. Because the aorta and other tissues used in this work to determine SSAO activity presented no inflammation, SSAO was not expressed in the blood vessels, whereas SSAO expression would have been induced in human brain microvessels, which are narrower and more vulnerable.

In cardiomyocytes and acinar cells, SSAO localization was mainly intracellular, but it was mainly membranous in adrenal gland, duodenum, liver, lung, and exocrine pancreas. Both liver and lung contribute to the degradation of physiological amines. The membrane and intracellular SSAO IR localization observed in these tissues suggests that it might also modulate hormonal action. Thus, as shown in adipocytes (Marti et al. 1998 ), in addition to its role as a scavenger of circulating amines, human SSAO might influence some physiological processes through the generation of H2O2 (Lyles 1996 ; Enrique-Tarancon et al. 1998 ). In spleen, SSAO in the capsule and trabeculae of the membrane of the smooth muscles may also have a role other than amine oxidation.

We found only two tissues devoid of SSAO IR: the thyroid gland, rich in MAO-A, and the endocrine pancreas, with MAO-A localized mainly in ß-cells and MAO-B restricted to {alpha}-cells (Rodriguez et al. 2000 ). The absence of SSAO IR in these two glands might indicate that MAO hydrogen peroxide generation may modulate hormone secretion without the participation of SSAO, as proposed by other authors (Pizzinat et al. 1999 ).

In conclusion, these results are the first attempt to quantify and map SSAO localization in human peripheral tissues. As suggested by its cell localization, its role may not be restricted to amine oxidation. Further experiments are necessary to provide such evidence and understand the physiological importance of SSAO in humans.


  Acknowledgments

Supported by SGR 99-224 from the Generalitat de Catalunya and the DGES grant SAF99-0093 from the Ministerio de Educación y Cultura.

We wish to thank Dr J. A. Bombí (Departament de Biologia Cel·lular i Anatomia Patològica, Facultat de Medicina, Universitat de Barcelona, Spain) for the gift of the human tissue samples, and Dr Ellen E. Billett (Department of Life Sciences, Faculty of Science and Mathematics, The Nottingham Trent University, UK) for the gift of the 9H7 antibody.

Received for publication May 18, 2000; accepted October 4, 2000.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Barrand MA, Fox SA, Callingham BA (1984) Amine oxidase activities in brown adipose tissue of the rat: identification of semicarbazide-sensitive (clorgyline resistant) activity at the fat cell membrane. J Pharm Pharmacol 38:288-293

Boomsma F, van der Veldhuise DJ, de Kam PJ, Man in't Veld AJ, Schalekamp MADH (1995) Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Life Sci 88:675-679

Bono P, Jalkanen S, Salmi P (1999) Mouse vascular adhesion protein-1 is a sialoglycoprotein with enzymatic activity and is induced in diabetic insulitis. Am J Pathol 155:1613-1624[Abstract/Free Full Text]

Bono P, Salmi M, Smith D, Jalkanen S (1998) Cloning and characterization of mouse vascular adhesion protein-1 reveals a novel molecule with enzymatic activity. J Immunol 160:5563-5571[Abstract/Free Full Text]

Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254[Medline]

Caldara R, Ferrari C, Romussi M, Bierti L, Gandini S, Curtarelli G (1978) Effect of dopamine infusion on gastric and pancreatic secretion and on gastric release in man. Gut 19:724-728[Abstract]

Castillo V, Lizcano JM, Visa J, Unzeta M (1998) Semicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterization. Neurochem Int 33:415-423[Medline]

Enrique–Tarancón G, Marti L, Morin N, Lizcano JM, Unzeta M, Sevilla L, Camps M, Palacín M, Testar X, Carpené C, Zorzano A (1998) Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem 273:8025-8032[Abstract/Free Full Text]

Fernández de Arriba A, Lizcano JM, Balsa D, Unzeta M (1991) Contribution of different amine oxidases to the metabolism of dopamine in bovine retina. Biochem Pharmacol 42:2355-2361[Medline]

Fowler CJ, Tipton KF (1981) Concentration-dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol 30:3319-3332

Hysmith RM, Boor PJ (1987) In vitro expression of benzylamine oxidase activity in cultured porcine smooth muscle cells. J Cardiovasc Pharmacol 9:668-674[Medline]

Jaakkola K, Kaunismäki K, Tohka S, Yegutkin G, Vänttinen E, Havia T, Pelliniemi LJ, Virolainen M, Jalkanen S, Salmi M (1999) Human vascular adhesion protein-1 in smooth muscle cells. Am J Pathol 155:1953-1965[Abstract/Free Full Text]

Lee MR (1982) Dopamine and the kidney. Clin Sci 62:439-448[Medline]

Lewinsohn R (1984) Mammalian monoamine-oxidizing enzymes with special reference to benzylamine oxidase in human tissues. Braz J Med Biol Res 17:223-256[Medline]

Lizcano JM, Escrich E, Ribalta T, Muntane J, Unzeta M (1991) Amine oxidases activities in rat breast cancer induced experimentally with 7,12-dimethyl-benz-alfa-anthracene. Biochem Pharmacol 42:263-269[Medline]

Lizcano JM, Tipton KF, Unzeta M (1998) Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem J 331:69-78[Medline]

Lyles GA (1996) Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical pharmacological and toxicological aspects. Int J Biochem Cell Biol 28:259-274[Medline]

Lyles GA, Callingham BA (1975) Evidence for a clorgyline-resistant monoamine metabolizing activity in rat heart. J Pharm Pharmacol 27:682-691

Magee DF (1989) Does the sympathetic nervous system regulate the exocrine pancreas? Int J Pancreatol 5:109-116[Medline]

Marti L, Morin N, Enrique–Taracón G, Prévot D, Lafontan M, Testar X, Zorzano A, Carpene C (1998) Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide. J Pharmacol Exp Ther 285:342-349[Abstract/Free Full Text]

Morel F, Surla A, Vignais P (1992) Purification of human placenta diamine oxidase. Biochem Biophys Res Commun 187:178-186[Medline]

Morgan DML (1985) Polyamine oxidases. Biochem Soc Trans 13:322-326[Medline]

Mori J, Satoh Y, Hashimoto M, Honda F (1979a) Amines and the rat exocrine pancreas: (1). Effects of receptor blockers on turnover of L-dopa. Jpn J Pharmacol 29:899-911[Medline]

Mori J, Satoh H, Satoh Y, Honda F (1979b) Amines and the rat exocrine pancreas: (3). Effects of amines on pancreatic secretion. Jpn J Pharmacol 29:923-933[Medline]

Morris NJ, Ducret A, Aebersold R, Ross SA, Keller SR, Lienhard GE (1997) Membrane amine oxidase cloning and identification as a major protein in the adipocyte plasma membrane. J Biol Chem 272:9388-9392[Abstract/Free Full Text]

Norqvist A, Fowler CJ, Oreland L (1981) The deamination of monoamines by pig dental pulp. Biochem Pharmacol 30:403-409[Medline]

Pizzinat N, Chan SLF, Remaury A, Morgan NG, Parini A (1999) Characterization of monoamine oxidase isoforms in human islets of Langerhans. Life Sci 65:441-448[Medline]

Precious E, Lyles GA (1988) Properties of semicarbazide-sensitive amine oxidase in human umbilical artery. J Pharm Pharmacol 40:627-633[Medline]

Rodríguez MJ, Saura J, Finch CC, Mahy N, Billett EE (2000) Localization of monoamine oxidase A and B in human pancreas, thyroid, and adrenal glands. J Histochem Cytochem 48:147-151[Abstract/Free Full Text]

Saura J, Andrés N, Andrade C, Ojuel J, Eriksson K, Mahy N (1997) Biphasic and region-specific MAO-B response to aging in normal human brain. Neurobiol Aging 18:497-507[Medline]

Saura J, Nadal E, van den Berg B, Vila M, Bombí JA, Mahy N (1996) Localization of monoamine oxidases in human peripheral tissues. Life Sci 59:1341-1349[Medline]

Saura J, Richards J, Mahy N (1994) Age-related changes of MAO in BL/C57 mouse tissues: a quantitative radioautographic study. J Neural Transm 41:89-94

Schwelberger HG, Bodner E (1997) Purification and characterization of diamine oxidase from porcine kidney and intestine. Biochim Biophys Acta 1340:152-164[Medline]

Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S (1998) Cloning of vascular adhesion protein-1 reveals a novel multifunctional adhesion molecule. J Exp Med 188:17-27[Abstract/Free Full Text]

Yu PH, Lai CT, Zuo DM (1997) Formation of formaldehyde from adrenaline in vivo: a potential risk factor for stress-related angiopathy. Neurochem Res 22:615-620[Medline]

Yu PH, Zuo DM, Davis BA (1994) Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Biochem Pharmacol 47:1055-1059[Medline]